A decline in neurogenesis in the hippocampus may underlie age-related memory impairment in rats and humans. We now show that WIN 55,212-2 administration for 3 weeks can partially restore neurogenesis in the hippocampus of aged rats. Cannabinoid receptor stimulation therapy may thus provide clinical benefit for humans with age-associated memory impairment.

The endocannabinoid system regulates some aspects of the brain\'s inflammatory response, including the release of pro-inflammatory cytokines and modulation of microglial activation.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ The endocannabinoid system is composed of two G-protein-coupled receptors designated as CB1 and CB2 expressed throughout the body and notably by neural stem cells.^[@bib5]^ We have previously shown that stimulation of the CB1/2 receptors using a low dose of WIN-55,212-2 significantly reversed the LPS-induced microglia activation in young rats.^[@bib2]^ This anti-inflammatory effect was also found in aged rats, attenuating the age-induced performance impairment observed in the water pool task.^[@bib3]^ As normal aging is associated with increased levels of microglial activation and a decrease in neurogenesis, both probably contributing to the hippocampus-related memory deficit, we investigated the effects of an agonist of CB1/2 receptors on neurogenesis in the brain of normal aged rats.

A total of 12 old (23-month-old) and 6 young (3-month-old) male F-344 rats were chronically infused for 28 days subcutaneously using an osmotic minipump with WIN-55,212-2 (2 mg kg^−1^ per day *n*=6) or the vehicle (*n*=12) into the dorsal abdominal area. Two injections of 50 mg kg^−1^ i.p. of 5-bromo-2-deoxyuridine were made on day 1 and day 2 post surgery to track new cells\' production. The rats were assigned to one of the following three groups: young+vehicle (*n*=6), old+vehicle (*n*=6) and old+WIN-55,212-2 2 mg kg^−1^ per day (*n*=6).

Doublecortin immunoreactivity was found only in the subgranular zone of the dentate gyrus (DG) of the hippocampus ([Figure 1A](#fig1){ref-type="fig"}). A significant difference ([Figure 1Aa--d](#fig1){ref-type="fig"}) in doublecortin immunoreactivity was found between young (3-month-old, 73.125±22.8 cells per DG) and old rats (23-month-old, 3±1.8 *P*\<0.05). The 4 weeks of WIN 55,212-2 infusion resulted in a significant increase in doublecortin immunoreactivity cells (+116%, F~1, 30~=6.774, *P*=0.0142, ANOVA with Fisher\'s PLSD *post-hoc* test) as compared with that in old vehicle-treated controls ([Figure 1B](#fig1){ref-type="fig"}).

5-bromo-2-deoxyuridine immunoreactivity was found sparsely in the cortex and hippocampus of the old vehicle-treated controls. The number of 5-bromo-2-deoxyuridine immunoreactivity cells was counted in the DG; the 4 weeks of WIN-55,212-2 infusion produced a significant increase in 5-bromo-2-deoxyuridine immunoreactivity cells (+63%, F~1, 221~=12.795, *P*=0.0004 ANOVA with Fisher\'s PLSD *post-hoc* test) as compared with that in old vehicle-treated controls ([Figure 1C](#fig1){ref-type="fig"}). The proportion of newly produced neurons over glial cells was determined and showed no significant difference between control or treated aged rats ([Figure 1D](#fig1){ref-type="fig"}, *P*=0.42), confirming the increase in number of neurons engrafted in the DG after the 4-week treatment.

Our results confirm that neurogenesis is still present during normal aging in rats, although at a drastically reduced level as compared with that in young rats, for review see Verret *et al.*^[@bib6]^ We now report that neurogenesis in aged rats can be significantly increased by a low, continuous, non-psychoactive dose of a cannabinoid receptor agonist, WIN-55,212-2. This report shows for the first time the potential therapeutic efficacy of endocannabinoid receptor stimulation in stimulating neurogenesis from proliferation to engraftment during normal aging *in vivo*. The current results, coupled with our previous observations regarding the role of endocannabinoid receptors,^[@bib3],\ [@bib4]^ underscores the potential clinical benefits of cannabinoid pharmacotherapies during normal and pathological brain aging.
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![(**A**) Doublecortin immunoreactivity (IR) in the dentate gyrus (DG). For all pictures, Doublecortin immunoreactivity (DCX-IR) is in green and NeuN-IR is in red. (**a**, **b**) 3-month-young rats, magnification × 600. (**c**, **d**) 23-month control rats, magnification × 600. (**e**, **f**) 23-month-old rats treated for 3 weeks with 2 mg kg^−1^ per day of WIN-55,212-2, magnification × 600. Note the significant decrease in DCX-IR between young (**a**, **b**) and aged control (**c**, **d**) rats, as well as the significant increase in DCX-IR between aged controls (**c**, **d**) and WIN-treated aged (**e**, **f**) rats. (**B**) Number of DCX-IR cells by DG: a significant increase (116%, ^\*^*P*\<0.05, Fisher\'s PLSD *post-hoc* test) of doublecortin immunoreactive cells was observed in the subgranular zone of the dentate gyrus of rats treated 3 weeks with 2 mg kg^−1^ per day of WIN-55,212-2. (**C**) 5-bromo-2-deoxyuridine (BrdU)-positive cells in the DG of aged animals: a significant increase (63%, ^\*^*P*\<0.05, Fisher\'s PLSD *post-hoc* test) of BrdU immunoreactive cells was observed in the subgranular zone of the dentate gyrus of rats treated for 3 weeks with 2 mg kg^−1^ per day of WIN-55,212-2. (**D**) Proportion of neurons/glia co-localized with BrdU cells in the DG of aged animals: no significant changes could be seen in the proportion of new neurons over new glial cells.](mp200962f1){#fig1}
